Idioma:

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects

Ghannad, M ; Dennehy, M ; la Porte, C ; Seguin, I ; Tardiff, D ; Mallick, R ; Sabri, E ; Zhang, G ; Kanji, S ; Cameron, D W De Socio, Giuseppe Vittorio

PloS one, 2019-10, Vol.14 (10), p.e0223969-e0223969 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects
Autor: Ghannad, M ; Dennehy, M ; la Porte, C ; Seguin, I ; Tardiff, D ; Mallick, R ; Sabri, E ; Zhang, G ; Kanji, S ; Cameron, D W
De Socio, Giuseppe Vittorio
Assuntos: Acquired immune deficiency syndrome ; Adolescent ; Adult ; Aged ; AIDS ; Anti-Bacterial Agents - pharmacokinetics ; Antibacterial agents ; Antiretroviral agents ; Antiretroviral drugs ; Biology and Life Sciences ; Care and treatment ; Chromatography ; Cytochrome P-450 ; Dosage and administration ; Drug dosages ; Drug interaction ; Drug Interactions ; Epidemiology ; Exposure ; Female ; Food ; Health aspects ; Healthy Volunteers ; High performance liquid chromatography ; HIV ; HIV Fusion Inhibitors - pharmacokinetics ; HIV infection ; HIV infections ; HIV patients ; Hospitals ; Human immunodeficiency virus ; Humans ; Infections ; Liquid chromatography ; Male ; Maraviroc ; Maraviroc - pharmacokinetics ; Mass spectrometry ; Mass spectroscopy ; Medicine and Health Sciences ; Middle Aged ; Pharmacokinetics ; Pharmacology ; Rifabutin ; Rifabutin - pharmacokinetics ; Rifamycins ; Spectroscopy ; Steady state ; Studies ; Tissue Distribution ; Tuberculosis ; Young Adult
É parte de: PloS one, 2019-10, Vol.14 (10), p.e0223969-e0223969
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: ViiV Healthcare, a Pfizer affiliate, funded this study. CLP began working for Janssen after the conclusion of the study. Janssen had no role in this study and did not contribute any funding. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Current address: The Janssen Pharmaceutical Companies of Johnson & Johnson, Breda, Netherlands
Descrição: Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days. On day six, rifabutin 300 mg once daily (QD, P.O.) was added to the regimen. Formal pharmacokinetic (PK) sampling was performed on days five and fifteen. Individual plasma drug concentration-time data for maraviroc, and rifabutin on day fifteen, were obtained using validated High Performance Liquid Chromatography (HPLC) tandem Mass Spectrometry (MS/MS). Rifabutin steady state exposure was comparable to data in the literature. Maraviroc area under the curve (AUC) and minimum plasma concentration (Clast or Cmin) were reduced by 17% and 30% respectively when co-administered with rifabutin. No unexpected or serious adverse eventsoccurred. Based on the reduced exposure of maraviroc observed in this study, increasing the dose of maraviroc may be studied to normalize its moderately reduced exposure following rifabutin co-administration, a moderate inducer of CYP3A4.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 6 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects

Ghannad, M ; Dennehy, M ; la Porte, C ; Seguin, I ; Tardiff, D ; Mallick, R ; Sabri, E ; Zhang, G ; Kanji, S ; Cameron, D W De Socio, Giuseppe Vittorio

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.